CNTNAP2-related developmental and epileptic encephalopathy

CNTNAP2-related developmental and epileptic encephalopathy is a rare genetic neurological disorder caused by pathogenic variants in the CNTNAP2 gene (also known as CASPR2), which encodes contactin-associated protein-like 2, a neuronal cell adhesion molecule critical for normal brain development and function. This condition is also referred to as Pitt-Hopkins-like syndrome 1 (PTHSL1) or cortical dysplasia-focal epilepsy syndrome (CDFE). The CNTNAP2 protein plays an essential role in the clustering of potassium channels at nodes of Ranvier and in neuronal migration during brain development. The disorder primarily affects the central nervous system and is characterized by early-onset seizures (typically beginning in infancy or early childhood), severe intellectual disability, language regression or absent speech, and features that may overlap with autism spectrum disorder. Additional clinical features can include cortical dysplasia on brain imaging, behavioral abnormalities, hyperactivity, and motor difficulties. Some patients may exhibit breathing irregularities and facial features reminiscent of Pitt-Hopkins syndrome, though typically milder. Seizures are often drug-resistant and may include multiple seizure types. There is currently no cure or disease-specific therapy for CNTNAP2-related developmental and epileptic encephalopathy. Management is supportive and symptomatic, focusing on seizure control with antiepileptic medications, speech and language therapy, occupational therapy, behavioral interventions, and special educational support. Given the frequent drug-resistance of seizures, a multidisciplinary approach involving pediatric neurology, developmental pediatrics, and rehabilitation specialists is essential for optimizing patient outcomes.

Common questions about CNTNAP2-related developmental and epileptic encephalopathy